No Data
【Brokerage Focus】CITIC SEC: The performance disparity in the Medical industry is accelerating, and policy trends are clear.
Jinwu Financial News | CITIC SEC stated that in 2024, the overall revenue of medical listed companies under the CITIC SEC industry classification will decrease by 0.62% year-on-year, with a net income attributable to the parent company declining by 8.48%. Both revenue and profit experience negative growth, while indicators such as gross margin, net margin, and Cash / Money Market / revenue have seen a decline compared to 2022 and 2023. In Q1 2025, the overall revenue of medical listed companies will decrease by 4.56% year-on-year, with a net income attributable to the parent company declining by 11.28%, putting pressure on performance. Although negative growth is still observed in the overall healthcare industry's performance for 2024 and Q1 2025, various subsidiary sectors are...
The Innovative Drugs Concept continues to adjust, BEIGENE (06160) drops 7.31%. Institutions indicate that the most worthy area of focus in the pharmaceutical Sector remains the Innovative Drugs track.
Jingwu Financial News | The Innovative Drugs Concept continues to adjust, with CanSino (01167) down 13.95%, BEIGENE (06160) down 7.31%, JUNSHI BIO (01877) down 6.75%, REMEGEN (09995) down 6.6%, and WUXI BIO (02269) down 6.24%. Sinolink's Research Reports indicate that the most noteworthy area in the pharmaceutical Sector will still be the Innovative Drugs track, as they believe that grasping investment opportunities in innovative pharmaceuticals will be the main theme of pharmaceutical investment throughout 2025, focusing on leading innovative drugs going overseas and leading combination of generics and innovative drugs, while also actively paying attention to...
Junshi Biosciences Gets Registration Certificate in China for 12th Indication of Melanoma Drug
Junshi Biotech\'s 2025 First Quarter Report
JUNSHI BIO (688180.SH) reported a net loss of 0.235 billion yuan in the first quarter.
Glory Exchange, April 25丨JUNSHI BIO (688180.SH) released its quarterly report, achieving total operating income of 0.501 billion yuan in the first quarter of 2025, a year-on-year increase of 31.46%; Net income attributable to shareholders of the parent company was -0.235 billion yuan, a decrease of 48.1529 million yuan compared to the same period last year; EPS is -0.24 yuan.
JUNSHI BIO (01877) announced its first quarter results, with a net loss attributable to parent company of approximately 0.235 billion yuan, narrowing by 17% year-on-year.
JUNSHI BIO (01877) announced its first quarter performance for 2025, with revenue of approximately 0.5 billion yuan, a year-on-year increase of 31....
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
